Biotech Values

[investorgold2002]

GILENYA & Copaxone

thanks dew again for your message

try below...it says Gilenya can ramp up to 1.5 bill by 2017 if no safety issues are found in the next few years. I guess Gilenya can take marketshare from copaxone as well as the infereons...But as you pointed out due it's safety and the fact it's been in market for more than a decade now, there is really no threat to Copaxone

http://www.in-thought.com/resources/GilenyaSurvey.WK.16Nov.pdf


Then I found the below

http://www.msworld.org/forum/showthread.php?t=110680

"There hasn't been a head to head study with these 2 DMDs to date that I'm aware of. I've always heard that Copaxone and Avonex have similar efficacy rates. Gilenya was 50% more effective in reducing relapses in a head to head trial with Avonex.
"

so i guess it's the safety(risk/benefit) which gives copaxone an edge ?